CSNK1A1 and B-cell chronic lymphocytic leukemia: This suggests that Wnt pathway inhibitors, including inhibitors of CK1(δ)/ε, can synergize with BTK inhibitors like ibrutinib in patients with CLL or other ROR1+ B-cell malignancies such as MCL.